jRCT2080223241未知1 期
Phase I Trial of YHI-1501 in Healthy Adult Japanese Subjects
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 68
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Randomized, single-center, double-blinded, placebo-controlled, dose-escalation study
入排标准
- 年龄范围
- 20age old over 至 44age old under（—）
- 性别
- Male
入选标准
- •Healthy male Japanese subjects
- •BMI of 18.5 kg/m^2 or more but less than 25.0 kg/m^2
排除标准
- •History of alcoholism
- •History of clinically significant drug or food allergies
- •History of surgery which affects oral drug absorption
结局指标
主要结局
-
Safety
次要结局
未报告次要终点
研究者
相似试验
未知
1 期
Phase I trial of YHI-1003 plus Bortezomib and DexamethasoneRelapsed Multiple Myeloma previously treated with BortezomibJPRN-jRCT2080221706Yakult Honsha Co., Ltd.18
进行中（未招募）
1 期
Phase I trial - 2021-006930-37The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has endedISRCTN15751828Omeros Corporation (United States)12
已完成
Unknown
Phase 1 trial: CA38951Healthy volunteersISRCTN46343886Millicent Pharma Limited36
未知
1 期
A phase I/II study in combination of YHI-1001 and Sorafenib in patients with advanced hepatocellular carcinoma previously untreated with systemic chemotherapypatients with advanced hepatocellular carcinoma previously untreated with systemic chemotherapyJPRN-jRCT2080222078Yakult Honsha Co., Ltd.164
已完成
不适用
YNP01 trial (YNP01 trial)patients with advanced or metastatic solid cancerjRCTs06118005818